Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript May 8, 2025Crinetics Pharmaceuticals, Inc. misses on earnings expectations.
Crinetics Pharmaceuticals Inc. (CRNX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Decheng Capital Min Cui | 177,958 | $5,968,711 | +6% | 1.67% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.06 | 5,000 | Director | 5,000 | 2023-06-08 | Filing | |
| $22.22 | 157,515 | Large Shareholder | 5,321,032 | 2022-04-18 | Filing | |
| $19.80 | 1,200,000 | Large Shareholder | 5,163,517 | 2021-10-25 | Filing | |
| $16.44 | 304,136 | Large Shareholder | 3,963,517 | 2021-04-08 | Filing | |
| $13.10 | 4,000 | Officer, Director | 4,000 | 2020-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $34.83 | 127 | 72,233 | 2025-03-19 | Filing | ||
| $34.17 | 2,388 | 72,360 | 2025-03-19 | Filing | ||
| $34.83 | 361 | 87,491 | 2025-03-19 | Filing | ||
| $34.17 | 6,801 | 87,852 | 2025-03-19 | Filing | ||
| $34.83 | 291 | 108,588 | 2025-03-19 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,311,600 | $312,311,064 | 0.01% | |
| 2. | 7,656,569 | $256,801,325 | 0.01% | |
| 3. | 2,119,767 | $71,096,987 | 0.05% | |
| 4. | 1,047,015 | $35,116,883 | 0.04% | |
| 5. | 753,527 | $25,273,296 | 0% |
News See All
11 Stocks That Will Bounce Back According to Analysts
Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the Federal Reserve and new trade developments.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, everyone. Welcome to the Crinetics Pharmaceuticals Fourth Quarter and Full-Year 2024 Financial Results Conference Call.
10 Worst Performing Mid Cap Stocks to Buy According to Analysts
Market analysts are increasingly highlighting mid-cap stocks as a potentially attractive investment opportunity, particularly in the current economic climate.
15 Stocks That Took a Nosedive in January
Historically, the S&P 500's performance in January sets the pace for the rest of the year.
Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks
Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q3 2024 Earnings Call Transcript
Operator: Welcome to the Crinetics Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q2 2024 Earnings Call Transcript
Operator: Good day everyone, and welcome to the Crinetics Pharmaceuticals Second Quarter 2024 Earnings Conference Call. [Operator Instructions]. Please note this call may be recorded.
Billionaire Hedge Funds
